Pheochromocytoma and Paraganglioma

Januszewicz, Andrzej; Prejbisz, Aleksander; Dobrowolski, Piotr; Januszewicz, Magdalena

doi:10.1007/978-3-030-45562-0_7

Cited by 2 publications

(3 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hypokalemia increases the risk of developing HTN-dependent organ complications and can induce the onset of dangerous arrhythmias [3]. Treatment-resistant HTN is a clinical situation when properly administered pharmacotherapy consisting of three or more drugs in optimal, best-tolerated doses and lifestyle modification fail to reduce systolic blood pressure and diastolic blood pressure values to < 140 mmHg and/or < 90 mmHg, respectively, as confirmed by 24-hour BP measurement or home BP measurements [4,5]. Patients require frequent internal medicine follow-up resulting from the high risk of developing HTN-dependent organ complications, including left ventricular hypertrophy, the development of arteriosclerosis with all its complications, and impaired renal function [4,5].…”

Section: Discussion An D Co N Cl U Sio N Smentioning

confidence: 99%

“…Treatment-resistant HTN is a clinical situation when properly administered pharmacotherapy consisting of three or more drugs in optimal, best-tolerated doses and lifestyle modification fail to reduce systolic blood pressure and diastolic blood pressure values to < 140 mmHg and/or < 90 mmHg, respectively, as confirmed by 24-hour BP measurement or home BP measurements [4,5]. Patients require frequent internal medicine follow-up resulting from the high risk of developing HTN-dependent organ complications, including left ventricular hypertrophy, the development of arteriosclerosis with all its complications, and impaired renal function [4,5]. Efforts should be made to establish good cooperation with the patient, as the regular intake of medications in appropriate doses is essential to gain control over the course of the disease.…”

Section: Discussion An D Co N Cl U Sio N Smentioning

confidence: 99%

See 1 more Smart Citation

Therapeutic problems in patients with congenital adrenal hyperplasia from 11-β-hydroxylase deficiency

Ptak,

Podyma,

Kajdaniuk

2024

Ann. Acad. Med. Siles.

View full text Add to dashboard Cite

Wrodzony przerost nadnerczy (<i>congenital adrenal hyperplasia</i> – CAH) z niedoborem 11-β-hydroksylazy stanowi niewielki procent ogólnej częstości występowania CAH w populacji. Opisywany przypadek dwóch sióstr dotyka problemów terapeutycznych napotykanych w czasie leczenia tego rzadkiego schorzenia. Autorzy przedstawiają trudności związane z doborem odpowiednich dawek substytucyjnych glikokortykosteroidów, które zapewnią dobrą kontrolę ciśnienia tętniczego i zapobiegną rozwojowi powikłań narządowych wywołanych nadciśnieniem tętniczym, a także utrzymają hirsutyzm na akceptowalnym poziomie przy jak najmniejszej liczbie powikłań stosowanego leczenia. W pracy podkreślono rolę współpracy na linii pacjent–lekarz, niezbędnej do osiągnięcia założonych celów terapeutycznych.

show abstract

Section: Discussion An D Co N Cl U Sio N Smentioning

confidence: 99%

Section: Discussion An D Co N Cl U Sio N Smentioning

confidence: 99%

Therapeutic problems in patients with congenital adrenal hyperplasia from 11-β-hydroxylase deficiency

Ptak,

Podyma,

Kajdaniuk

2024

Ann. Acad. Med. Siles.

View full text Add to dashboard Cite

show abstract

“…Although in silico studies in the context of the impact of the rs4646994 polymorphism on treatment with ACEi drugs have already been conducted, their main target was usually captopril or lisinopril [44,45]. In this study, the interactions between two ACE domains and four drugs that are registered in Poland as those that can be used in the treatment of diabetic nephropathy [46] were taken into account. It should be remembered here that the I allele of the rs4646994 polymorphism causes premature codon termination, resulting in the enzyme having only one active site in the N domain [12].…”

Section: Discussionmentioning

confidence: 99%

The Role of Angiotensin-Converting Enzyme (ACE) Polymorphisms in the Risk of Development and Treatment of Diabetic Nephropathy

Król-Kulikowska,

Abramenko,

Jakubek

et al. 2024

JCM

View full text Add to dashboard Cite

Background: Angiotensin-converting enzyme (ACE) is responsible for the production of angiotensin II, and increased production of angiotensin II is observed in diabetes. What is more, ACE polymorphisms may play a role in the development of diabetic nephropathy. The aim of this study was to assess the role of selected ACE polymorphisms (rs4343 and rs4646994) in the risk of development of diabetic nephropathy and in the likelihood of renal replacement therapy. Methods: ACE polymorphisms were analyzed in a group of 225 patients who were divided into three subgroups. The rs4343 polymorphism was determined using the PCR-RFLP, and the rs4646994 polymorphism was determined using the PCR. Molecular docking between domains of ACE and its ligands was performed by using AutoDock Vina. Results: The G/G genotype of rs4343 polymorphism is associated with increased odds of developing diabetic nephropathy. The G allele is also associated with a higher risk of this disease. Similar results were obtained in patients who had already had a kidney transplant as a result of diabetic nephropathy. Conclusions: The presence of G/G and G/A genotypes, and the G allele increases the likelihood of developing diabetic nephropathy. This may also be a risk factor for renal replacement therapy.

show abstract

Pheochromocytoma and Paraganglioma

Cited by 2 publications

References 46 publications

Therapeutic problems in patients with congenital adrenal hyperplasia from 11-β-hydroxylase deficiency

Therapeutic problems in patients with congenital adrenal hyperplasia from 11-β-hydroxylase deficiency

The Role of Angiotensin-Converting Enzyme (ACE) Polymorphisms in the Risk of Development and Treatment of Diabetic Nephropathy

Contact Info

Product

Resources

About